Arginase 1 deficiency: a treatable form of spastic paraplegia.

Alessandro Burlina, Anna Ardissone, Carlo Dionisi Vici, Serena Gasperini, Alberto Burlina, Francesco Porta, Roberta Battini, Andrea Pession

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025;46(9):4219-4228

PMID: 40237972

Abstract

BACKGROUND

Arginase 1 deficiency (ARG1-D) is a rare hereditary urea cycle disorder characterized by elevated arginine levels, resulting in progressive neurological impairment and severe physical and cognitive disability. Due to its low prevalence, overlapping symptoms with other neurological disorders, and current limitations in newborn screening tools, ARG1-D is often misdiagnosed or diagnosed late, limiting access to early interventions.

AIM

This review and expert opinion aim to provide an overview of the clinical manifestations, diagnostic challenges, and treatment options for ARG1-D, offering a practical resource for specialists to recognize this rare, progressive, yet treatable disease.

RESULTS

ARG1-D typically presents with progressive spastic paraplegia, developmental delays, cognitive impairment, and seizures, with symptom onset and severity varying by age. Differential diagnoses mainly include hereditary spastic paraplegia, cerebral palsy, and hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, each with distinct clinical features and biochemical markers. Potential red flags for ARG1-D include elevated plasma arginine levels, spasticity, seizures, and cognitive impairment. These should prompt further examinations to confirm the diagnosis, which is based on biochemical assays for hyperargininemia and on genetic testing. Once confirmed, early treatment is advised, including dietary protein restriction, ammonia scavengers, antiepileptic drugs, and novel therapies, such as pegzilarginase, which targets the disease's metabolic root.

CONCLUSION

Experts stress the importance of increased awareness of ARG1-D characteristics, noting that early recognition and treatment are crucial to patient outcomes. Greater recognition of ARG1-D's distinctive features, differential diagnosis, and diagnostic tools, even among non-specialist clinicians, could help prevent misdiagnoses and facilitate the identification of this rare yet treatable condition.

© 2025. The Author(s).

Address: Dept. of Medicine, Neurology Unit, St. Bassiano Hospital, Via dei Lotti 40, 36061, Bassano del Grappa, Italy. [email protected].; Child Neurology Unit, Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.; Department of Neuroscience, IRCCS Stella Maris Foundation, Calambrone, Pisa, Italy.; Division of Inherited Metabolic Diseases, Department of Woman's and Child's Health, University Hospital, 35129, Padua, Italy.; Department of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.; Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138, Bologna, Italy.; Department of Pediatrics, AOU Citta' della Salute e della Scienza di Torino, 10126, Torino, Italy.; Division of Metabolic Diseases and Hepatology, Bambino Gesù Childrens Hospital IRCCS, Rome, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.